Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gracell Biotechnologies Inc ADR (NQ: GRCL )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gracell Biotechnologies Inc ADR

< Previous 1 2 3 4 5 6 Next >
Gracell Biotechnologies Acquisition Completed
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is a Stock Spotlight on 2/7
Via Investor Brand Network
Health Care Company AstraZeneca Announces Acquisition of Gracell Biotechnologies
Via Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. 
Via Talk Markets
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma 
From Gracell Biotechnologies Inc.
Via GlobeNewswire
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
In a significant development, the FDA is set to impose a classwide black box warning following its investigation into secondary T-cell cancers arising from the use of existing CAR-T therapies.  
Via Benzinga
Exposures Product Safety
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
AstraZeneca: Rebound in 2024 with double-digit earnings growth
AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisition 
Via MarketBeat
Exposures COVID-19
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
Key Takeaways: AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price 
Via Benzinga
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
From Kahn Swick & Foti, LLC
Via Business Wire
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program.... 
Via Talk Markets
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
The major indexes boast big annual gains with the Dow at record highs. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Investor Sentiment Improves; Dow Jumps Over 150 Points
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday. The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth... 
Via Benzinga
Crude Oil Rises Over 3%; US Home Prices Increase In October
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday. The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket
Shares of Sentage Holdings Inc. (NASDAQ: SNTG) shares moved lower in pre-market trading following results for the six months ended June 30, 2023. 
Via Benzinga
US Stocks Set To Start Final Trading Week Of Year On Positive Note As Santa Claus Rally Gets Going: Analyst Confident Of Market Finishing Year At Highs
Stocks appear on track to start Tuesday's session on a positive note amid positive expectations concerning interest rates and economy. 
Via Benzinga
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Gracell Biotechnologies Inc (NASDAQ: GRCL), further strengthening AstraZeneca's cell therapy portfolio. 
Via Benzinga
Gracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 40 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
From AstraZeneca
Via Business Wire
Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases
From Gracell Biotechnologies Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.